secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-11-25T23:59:59+00:00
Accession:  0001493152-25-024996
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 3.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LIXTE acquires Liora Technologies' proton therapy platform; consideration includes stock, crypto, cash, royalty
--------------------------------------------------------------------------------

- Consideration: 2,700 Series C Preferred shares (convertible to 2.7M common), 10.56 BTC + 300 ETH, $440K cash, and 10% royalty on net revenue up to $45M.
- Liora's LiGHT proton therapy system installed at Daresbury Laboratory in UK; $300M+ invested to date.
- Acquisition closed Nov 24, 2025; Liora becomes wholly owned subsidiary of LIXTE.
- Series C Preferred is non-voting, convertible subject to 19.99% limit until shareholder approval at 2026 annual meeting.
- CEO says LiGHT platform complements LB-100 pipeline and enables potential recurring revenue model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225024996/0001493152-25-024996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225024996/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-024996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer